Cellura is proud to announce its participation in the 3rd edition of the Innovations for Cell and Gene Therapies (ICGT) Congress, taking place on May 27–28, 2026 at the Sanofi Campus in Gentilly, France.
Organized by MabDesign in collaboration with the French Society for Cell and Gene Therapy (SFTCG), ICGT has rapidly established itself as one of the major European congresses focused on the future of cell and gene therapies, bringing together researchers, clinicians, biotech companies, pharmaceutical leaders and industrial experts working across the entire advanced therapy ecosystem.
The congress is designed as a meeting point between scientific innovation, translational medicine and industrial bioproduction. Over two days, participants will discuss the latest advances shaping the future of regenerative medicine and next-generation therapeutics, with a strong emphasis on the technological and manufacturing challenges associated with clinical deployment.
This year’s edition will notably explore emerging fields such as CAR-T and CAR-NK therapies, RNA and mRNA therapeutics, gene editing technologies, organoids, extracellular vesicles, advanced 3D cellular models and scalable GMP-oriented manufacturing strategies.
Beyond scientific presentations, ICGT also integrates technology exhibitions, breakthrough innovation sessions and dedicated B2B meetings, creating a highly collaborative environment where academia, biotech and industry can interact directly around future therapeutic challenges.
As advanced therapies continue to evolve toward larger-scale clinical applications, congresses such as ICGT are becoming increasingly strategic. The field is now entering a phase where the ability to manufacture fragile cellular products reproducibly and efficiently is becoming just as important as the therapeutic innovation itself.
Why scalable and reproducible cell production has become a central challenge
Modern cell and gene therapies increasingly rely on highly sensitive biological systems. From pluripotent stem cells and engineered immune cells to organoids and patient-derived cellular models, these advanced biological platforms require culture environments capable of preserving cellular integrity throughout the entire production process.
However, one of the major limitations of conventional bioreactor systems remains the increase of mechanical stress during scale-up. Traditional agitation technologies based on impellers or bubbling often generate heterogeneous environments that can compromise cell viability, alter phenotype stability and reduce reproducibility between batches.
This challenge becomes particularly critical in advanced therapies, where even subtle variations in culture conditions can directly impact translational reliability and therapeutic outcomes.
As a result, the sector is increasingly focusing on technologies capable of combining:
- Gentle culture conditions
- Homogeneous nutrient and oxygen distribution
- Scalable production strategies
- Reproducibility from research to GMP environments
The industrialization of advanced therapies now depends not only on biological discoveries, but also on the development of bioproduction technologies capable of supporting fragile cells at scale.
Cellura’s approach to the future of fragile cell bioproduction
At ICGT 2026, Cellura will present its vision for next-generation cell culture through the SoftXS™ low-shear bioreactor platform, developed specifically for highly sensitive cells.
The technology relies on a patented bladeless mixing system inspired by Earth’s rotational dynamics, generating controlled chaotic flow while minimizing mechanical stress on cells. This geo-inspired approach was designed to address one of the major bottlenecks in advanced therapy manufacturing: maintaining gentle and homogeneous suspension conditions while enabling scalability.
Unlike conventional stirred systems, where shear stress often increases significantly with production volume, SoftXS™ was engineered to preserve controlled low-shear conditions throughout the scale-up process.
This approach is particularly relevant for applications involving:
- iPSC expansion
- Immune cell manufacturing
- Organoid cultivation
- Microcarrier-based cultures
- Advanced 3D therapeutic models
The platform has already demonstrated proof-of-concept applications across several sensitive cellular systems, supporting Cellura’s objective of enabling more reproducible and scalable bioproduction strategies for advanced therapies.
Recent experimental work on microcarrier suspension also demonstrated the platform’s ability to maintain homogeneous suspension conditions under extremely low-shear environments compared with conventional stirred systems. These types of capabilities are becoming increasingly important as the industry moves toward larger-scale and more standardized manufacturing workflows.
Bridging scientific innovation and industrial reality
One of the defining characteristics of ICGT is its strong focus on the transition between laboratory innovation and industrial deployment.
The future of cell and gene therapies will not rely solely on therapeutic breakthroughs. It will also depend on the ability to manufacture complex cellular products under controlled, reproducible and scalable conditions compatible with future clinical and industrial requirements.
This evolution is driving increasing attention toward technologies capable of simplifying process transfer between research and production environments while maintaining biological quality and operational consistency.
In this context, Cellura’s participation reflects a broader commitment to contributing to discussions surrounding:
- Scalable 3D cell culture
- Low-shear bioproduction
- Process reproducibility
- Future GMP-compatible workflows
- Industrialization of fragile cell systems
As advanced therapies continue to mature, the technologies supporting cell cultivation and expansion are becoming a strategic component of the entire therapeutic value chain.
A growing ecosystem dedicated to next-generation therapies
The ICGT Congress continues to position itself as a major European ecosystem for collaboration between research institutions, biotech companies, pharmaceutical groups, CDMOs and technology developers working in advanced therapies.
By participating in ICGT 2026, Cellura aims to engage with the broader scientific and industrial community involved in shaping the future of regenerative medicine and scalable cell manufacturing.
The congress reflects the growing convergence between biology, engineering and industrial bioproduction, a convergence that will play a defining role in the next generation of therapeutic innovation.
Cellura is proud to contribute to this new edition and to support the development of gentle, scalable and reproducible 3D cell production technologies adapted to the future needs of advanced therapies.
About the event
More information about ICGT Congress is available on the official website: https://icgtcongress.com/
For further information or to arrange a meeting:
Email: contact@cellura.io
